IER5L is a Prognostic Biomarker in Pan-Cancer Analysis and Correlates with Immune Infiltration and Immune Molecules in Non-Small Cell Lung Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke AP, et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015;10(9):1240–1242. doi:10.1097/jto.0000000000000663
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594. doi:10.4065/83.5.584
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (Concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi:10.1016/s0140-6736(17)33326-3
   PubMed Web of Science ®Google Scholar
• Stella GM, Luisetti M, Pozzi E, et al. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med. 2013;1:251–261. doi:10.1016/s2213-2600(13)70009-2
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature25183
   PubMed Web of Science ®Google Scholar
• Zhu W, Shi L, Gong Y, et al. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway. Thorac Cancer. 2022;13:1027–1039. doi:10.1111/1759-7714.14354
   PubMed Web of Science ®Google Scholar
• Zhang C, Huang J, Lou K, et al. Long noncoding RNASEH1-AS1 exacerbates the progression of non-small cell lung cancer by acting as a ceRNA to regulate microRNA-516a-5p/FOXK1 and thereby activating the Wnt/β-catenin signaling pathway. Cancer Med. 2022;11:1589–1604. doi:10.1002/cam4.4509
   PubMed Web of Science ®Google Scholar
• Liang H, Chen Q, Hu Z, et al. Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis. Ann Transl Med. 2022;10(6):281. doi:10.21037/atm-22-764
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang N, Zhang Y, et al. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. Invest New Drugs. 2022;40(1):43–57. doi:10.1007/s10637-021-01159-6
   PubMed Web of Science ®Google Scholar
• Hu X, Xu H, Xue Q, et al. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Mol Med. 2021;27(1):126. doi:10.1186/s10020-021-00387-z
   PubMed Web of Science ®Google Scholar
• Miao TW, Chen FY, Du LY, et al. Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. Front Genet. 2022;13:930826. doi:10.3389/fgene.2022.930826
   PubMedGoogle Scholar
• Liu XG, Li M, Mai SJ, et al. Telomere length-related signature as a novel biomarker of prognosis and immune response in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2022;26(4):1304–1319. doi:10.26355/eurrev_202202_28124
   PubMed Web of Science ®Google Scholar
• Li M, Zhang Y, Fan M, et al. Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC. BMC Med Genomics. 2021;14(1):286. doi:10.1186/s12920-021-01133-4
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhou D, Wu F, et al. Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer. Front Oncol. 2021;11:680287. doi:10.3389/fonc.2021.680287
   PubMed Web of Science ®Google Scholar
• Fang C, Liu F, Wang Y, et al. A innovative prognostic symbol based on neutrophil extracellular traps (NETs)-related lncRNA signature in non-small-cell lung cancer. Aging. 2021;13(13):17864–17879. doi:10.18632/aging.203289
   PubMedGoogle Scholar
• Yao J, Li R, Liu X, et al. Prognostic implication of glycolysis related gene signature in non-small cell lung cancer. J Cancer. 2021;12(3):885–898. doi:10.7150/jca.50274
   PubMed Web of Science ®Google Scholar
• Ueda T, Kohama Y, Sakurai H. IER family proteins are regulators of protein phosphatase PP2A and modulate the phosphorylation status of CDC25A. Cell Signal. 2019;55:81–89. doi:10.1016/j.cellsig.2018.12.012
   PubMed Web of Science ®Google Scholar
• Vastrad C, Vastrad B. Bioinformatics analysis of gene expression profiles to diagnose crucial and novel genes in glioblastoma multiform. Pathol Res Pract. 2018;214(9):1395–1461. doi:10.1016/j.prp.2018.07.015
   PubMed Web of Science ®Google Scholar
• Zou J, Zhang H, Huang Y, et al. Multi-Omics Analysis of the Tumor Microenvironment in Liver Metastasis of Colorectal Cancer Identified FJX1 as a Novel Biomarker. Front Genet. 2022;13:960954. doi:10.3389/fgene.2022.960954
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019:47:D607–d613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Song T, Xu A, Zhang Z, et al. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075. J Cell Physiol. 2019;234(8):14296–14305. doi:10.1002/jcp.28128
   PubMed Web of Science ®Google Scholar
• Yan S, Han B, Gao S, et al. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget. 2017;8(36):60149–60158. doi:10.18632/oncotarget.18557
   PubMedGoogle Scholar
• Zacksenhaus E, Shrestha M, Liu JC, et al. Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: implications for Anabolic Metabolism, Stemness, and Metastasis. Trends Cancer. 2017;3(11):768–779. doi:10.1016/j.trecan.2017.09.002
   PubMed Web of Science ®Google Scholar
• Nie W, Hu MJ, Zhang Q, et al. DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation. Acta Pharmacol Sin. 2022;43:157–166. doi:10.1038/s41401-021-00624-5
   PubMed Web of Science ®Google Scholar
• Zhang J, Yan L, Wei P, et al. PEG-GO@XN nanocomposite suppresses breast cancer metastasis via inhibition of mitochondrial oxidative phosphorylation and blockade of epithelial-to-mesenchymal transition. Eur J Pharmacol. 2021;895:173866. doi:10.1016/j.ejphar.2021.173866
   PubMed Web of Science ®Google Scholar
• Allen TD, Rodriguez EM, Jones KD, et al. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 2011;71(18):6010–6018. doi:10.1158/0008-5472.can-11-0595
   PubMed Web of Science ®Google Scholar
• Aster JC, Pear WS, Blacklow SC. The Varied Roles of Notch in Cancer. Annu Rev Pathol. 2017;12(1):245–275. doi:10.1146/annurev-pathol-052016-100127
   PubMedGoogle Scholar
• Sharif A, Shaji A, Chammaa M, et al. Notch Transduction in Non-Small Cell Lung Cancer. Int J Mol Sci. 2020;22(1):21. doi:10.3390/ijms21165691
   PubMedGoogle Scholar
• Li X, Wang Y, Li X, et al. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC. Front Immunol. 2021;12:638763. doi:10.3389/fimmu.2021.638763
   PubMed Web of Science ®Google Scholar
• Chen CY, Chen YY, Hsieh MS, et al. Expression of Notch Gene and Its Impact on Survival of Patients with Resectable Non-small Cell Lung Cancer. J Cancer. 2017;8(7):1292–1300. doi:10.7150/jca.17741
   PubMed Web of Science ®Google Scholar
• Donnem T, Andersen S, Al-Shibli K, et al. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer. 2010;116(24):5676–5685. doi:10.1002/cncr.25551
   PubMed Web of Science ®Google Scholar
• Yuan X, Wu H, Xu H, et al. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Sci Rep. 2015;5(1):10338. doi:10.1038/srep10338
   PubMed Web of Science ®Google Scholar
• Yuan X, Wu H, Xu H, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369(1):20–27. doi:10.1016/j.canlet.2015.07.048
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Bagheri L, Badreldin A, et al. Biological Effects of Gyrophoric Acid and Other Lichen Derived Metabolites, on Cell Proliferation, Apoptosis and Cell Signaling pathways. Chem Biol Interact. 2022;351:109768. doi:10.1016/j.cbi.2021.109768
   PubMed Web of Science ®Google Scholar
• Fagundes R, Teixeira LK. Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability. Front Cell Dev Biol. 2021;9:774845. doi:10.3389/fcell.2021.774845
   PubMed Web of Science ®Google Scholar
• Yoshioka KI, Kusumoto-Matsuo R, Matsuno Y, et al. Genomic Instability and Cancer Risk Associated with Erroneous DNA Repair. Int J Mol Sci. 2021;23(1):22. doi:10.3390/ijms222212254
   PubMedGoogle Scholar
• Klempner SJ, Fabrizio D, Bane S, et al. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: a Review of Current Evidence. Oncologist. 2020;25:e147–e159. doi:10.1634/theoncologist.2019-0244
   PubMed Web of Science ®Google Scholar
• Bian X, Xiao YT, Wu T, et al. Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. Mol Cancer. 2019;18(1):50. doi:10.1186/s12943-019-0973-7
   PubMed Web of Science ®Google Scholar
• Suzuki J, Aokage K, Neri S, et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021;153:1–10. doi:10.1016/j.lungcan.2020.12.020
   PubMed Web of Science ®Google Scholar
• Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3 + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107(12):2866–2872. doi:10.1002/cncr.22282
   PubMed Web of Science ®Google Scholar
• Kang DH, Chung C, Sun P, et al. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. Cancer Immunol Immunother. 2022;71(3):579–588. doi:10.1007/s00262-021-03018-y
   PubMed Web of Science ®Google Scholar
• Wang W, Hodkinson P, McLaren F, et al. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer. 2012:131:E928–937. doi:10.1002/ijc.27613
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang SJ, et al. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179. doi:10.1038/srep15179
   PubMed Web of Science ®Google Scholar
• Wang X, Xiao Z, Gong J, et al. A prognostic nomogram for lung adenocarcinoma based on immune-infiltrating Treg-related genes: from bench to bedside. Transl Lung Cancer Res. 2021;10(1):167–182. doi:10.21037/tlcr-20-822
   PubMed Web of Science ®Google Scholar
• Zhang L, Yi H, Chen J, et al. Neutrophil Extracellular Traps Facilitate A549 Cell Invasion and Migration in a Macrophage-Maintained Inflammatory Microenvironment. Biomed Res Int. 2022;2022:8316525. doi:10.1155/2022/8316525
   PubMed Web of Science ®Google Scholar
• Varim C, Celik FD, Sunu C, et al. The role of neutrophil albumin ratio in predicting the stage of non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2022;26:2900–2905. doi:10.26355/eurrev_202204_28621
   PubMed Web of Science ®Google Scholar
• Stares M, Ding TE, Stratton C, et al. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open. 2022;7(2):100445. doi:10.1016/j.esmoop.2022.100445
   PubMed Web of Science ®Google Scholar
• Tyagi A, Wu SY, Sharma S, et al. Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis. Oncogene. 2022;41(22):3079–3092. doi:10.1038/s41388-022-02322-w
   PubMed Web of Science ®Google Scholar
• Zhong R, Chen D, Cao S, et al. Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq. Clin Transl Oncol. 2021;23:405–417. doi:10.1007/s12094-020-02435-2
   PubMed Web of Science ®Google Scholar
• Széles Á, Fazekas T, Váncsa S, et al. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Cancer Immunol Immunother. 2023;72(5):1061–1073. doi:10.1007/s00262-022-03328-9
   PubMed Web of Science ®Google Scholar
• Moran JA, Adams DL, Edelman MJ, et al. Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. JCO Precis Oncol. 2022:6:e2200457. doi:10.1200/po.22.00457
   PubMed Web of Science ®Google Scholar
• Sánchez-Magraner L, Gumuzio J, Miles J, et al. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol. 2023;41(14):2561–2570. doi:10.1200/jco.22.01748
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ma Y, Zang A, et al. First-in-human Phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol. 2023;16(1):50. doi:10.1186/s13045-023-01445-1
   PubMed Web of Science ®Google Scholar